Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.

Ferrari G, Pollara J, Tomaras GD, Haynes BF.

J Infect Dis. 2017 Mar 15;215(suppl_3):S152-S159. doi: 10.1093/infdis/jiw555.

2.

Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.

Brandenberg OF, Magnus C, Rusert P, Günthard HF, Regoes RR, Trkola A.

PLoS Pathog. 2017 May 4;13(5):e1006313. doi: 10.1371/journal.ppat.1006313. eCollection 2017 May.

3.

Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.

Alvarez RA, Maestre AM, Law K, Durham ND, Barria MI, Ishii-Watabe A, Tada M, Kapoor M, Hotta MT, Rodriguez-Caprio G, Fierer DS, Fernandez-Sesma A, Simon V, Chen BK.

JCI Insight. 2017 Feb 23;2(4):e88226. doi: 10.1172/jci.insight.88226.

4.

Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.

Go EP, Ding H, Zhang S, Ringe RP, Nicely N, Hua D, Steinbock RT, Golabek M, Alin J, Alam SM, Cupo A, Haynes BF, Kappes JC, Moore JP, Sodroski JG, Desaire H.

J Virol. 2017 Apr 13;91(9). pii: e02428-16. doi: 10.1128/JVI.02428-16. Print 2017 May 1.

PMID:
28202756
5.

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Fuchs SP, Desrosiers RC.

Mol Ther Methods Clin Dev. 2016 Nov 16;3:16068. doi: 10.1038/mtm.2016.68. eCollection 2016. Review.

6.

Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.

Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME.

J Immunol Methods. 2017 Apr;443:33-44. doi: 10.1016/j.jim.2017.01.010. Epub 2017 Feb 3.

7.

Systems serology for evaluation of HIV vaccine trials.

Ackerman ME, Barouch DH, Alter G.

Immunol Rev. 2017 Jan;275(1):262-270. doi: 10.1111/imr.12503. Review.

PMID:
28133810
8.

Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.

Brady JM, Baltimore D, Balazs AB.

Immunol Rev. 2017 Jan;275(1):324-333. doi: 10.1111/imr.12478. Review.

PMID:
28133808
9.

Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.

Borrow P, Moody MA.

Immunol Rev. 2017 Jan;275(1):62-78. doi: 10.1111/imr.12504. Review.

10.

Use of broadly neutralizing antibodies for HIV-1 prevention.

Pegu A, Hessell AJ, Mascola JR, Haigwood NL.

Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511. Review.

PMID:
28133803
11.

Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.

Jaworski JP, Vendrell A, Chiavenna SM.

Front Immunol. 2017 Jan 11;7:661. doi: 10.3389/fimmu.2016.00661. eCollection 2016. Review.

12.

Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.

Bruel T, Guivel-Benhassine F, Lorin V, Lortat-Jacob H, Baleux F, Bourdic K, Noël N, Lambotte O, Mouquet H, Schwartz O.

J Virol. 2017 Mar 29;91(8). pii: e02440-16. doi: 10.1128/JVI.02440-16. Print 2017 Apr 15.

PMID:
28122982
13.

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.

Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJ, Watts RJ, Couch JA, Meng YG, Atwal JK, Brezski RJ, Spiess C, Ernst JA.

J Biol Chem. 2017 Mar 3;292(9):3900-3908. doi: 10.1074/jbc.M116.767749. Epub 2017 Jan 11.

PMID:
28077575
14.

IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.

Boesch AW, Miles AR, Chan YN, Osei-Owusu NY, Ackerman ME.

MAbs. 2017 Apr;9(3):455-465. doi: 10.1080/19420862.2016.1274845. Epub 2017 Jan 5.

PMID:
28055295
15.

Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses.

Boesch AW, Osei-Owusu NY, Crowley AR, Chu TH, Chan YN, Weiner JA, Bharadwaj P, Hards R, Adamo ME, Gerber SA, Cocklin SL, Schmitz JE, Miles AR, Eckman JW, Belli AJ, Reimann KA, Ackerman ME.

Front Immunol. 2016 Dec 13;7:589. doi: 10.3389/fimmu.2016.00589. eCollection 2016.

16.

Progress toward active or passive HIV-1 vaccination.

Escolano A, Dosenovic P, Nussenzweig MC.

J Exp Med. 2017 Jan;214(1):3-16. doi: 10.1084/jem.20161765. Epub 2016 Dec 21. Review.

PMID:
28003309
17.

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.

Astronomo RD, Santra S, Ballweber-Fleming L, Westerberg KG, Mach L, Hensley-McBain T, Sutherland L, Mildenberg B, Morton G, Yates NL, Mize GJ, Pollara J, Hladik F, Ochsenbauer C, Denny TN, Warrier R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Ferrari G, Shaw GM, Xia SM, Liao HX, Montefiori DC, Tomaras GD, Haynes BF, McElrath JM.

EBioMedicine. 2016 Dec;14:97-111. doi: 10.1016/j.ebiom.2016.11.024. Epub 2016 Nov 21.

18.

Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.

Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME.

J Immunol. 2016 Dec 15;197(12):4603-4612. Epub 2016 Nov 9.

PMID:
27913647
19.
20.

Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization.

Yamamoto H, Matano T.

Front Microbiol. 2016 Nov 2;7:1739. eCollection 2016. Review.

Supplemental Content

Support Center